Gemini Therapeutics, Inc. GMTX
1.35 0.00 (+0.00%)
At closeDec 30, 2022, 12:00 AM EST
1.35 Day range 1.41
52-week range unavailable
News
businesswire.com Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin's Tumor-Targeted Delivery and Cardiac-Safety Profile SAN FRANCISCO--(BUSINESS WIRE)-- #ASCO--Gemini Therapeutics Announces ASCO 2026 Analyses Supporting Aldoxorubicin's Tumor-Targeted Delivery and Cardiac-Safety Profile.
cnbc.com FDA reversals leave investors worrying about the fates of other experimental drugs The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing…
defenseworld.net iBio (NASDAQ:IBIO) versus Gemini Therapeutics (NASDAQ:GMTX) Critical Review iBio (NASDAQ: IBIO - Get Free Report) and Gemini Therapeutics (NASDAQ: GMTX - Get Free Report) are both manufacturing companies, but which is the superior stock? We will contrast the two companies…
defenseworld.net Gemini Therapeutics (NASDAQ:GMTX) Shares Down 2.6% – What’s Next? Shares of Gemini Therapeutics, Inc. (NASDAQ: GMTX - Get Free Report) fell 2.6% on Thursday. The company traded as low as $79.0933 and last traded at $80.01. 413,096 shares traded hands during…
investorplace.com 7 Short-Squeeze Stocks for Bold Contrarians to Consider Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's…
prnewswire.com SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
headlinesoftoday.com GEMINI THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Gemini Therapeutics, Inc. – GMTX NEW ORLEANS, Sept. 21, 2022 /PRNewswire/ — Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of…
prnewswire.com SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates GMTX, MANT, ZY, LOTZ NEW YORK , Aug. 11, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
zacks.com Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
benzinga.com 46 Biggest Movers From Yesterday Gainers Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday.
benzinga.com Gemini Therapeutics Shares Jump As HC Wainwright Sees Over 500% Upside H.C. Wainwright initiated coverage of Gemini Therapeutics Inc (NASDAQ: GMTX) with a Buy rating and $20 price target. In the near term, the expected Phase 2a readout for lead asset GEM103 can serve as…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 
businesswire.com Gemini Therapeutics to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular…
zacks.com Should You Buy Gemini Therapeutics (GMTX) Ahead of Earnings? Gemini Therapeutics (GMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
pulse2.com GMTX Stock: Why It Fell This Week The stock price of Gemini Therapeutics Inc (NASDAQ: GMTX) fell over 10% this week. This is why it happened.
businesswire.com Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular…
zacks.com Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock? Investors need to pay close attention to Gemini Therapeutics (GMTX) stock based on the movements in the options market lately.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 155 companies achieved new lows for the year.
benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday morning, 173 companies reached new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 282 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday morning, 207 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's morning session, 216 companies made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday Monday morning saw 115 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday morning, 158 companies reached new 52-week lows.
- benzinga.com 45 Biggest Movers From Yesterday Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.
- benzinga.com 31 Stocks Moving In Wednesday's Mid-Day Session Gainers Entera Bio Ltd. (NASDAQ: ENTX) shares jumped 58% to $7.09 after the company reported topline Phase 2 bone mineral density data for EB613.
- benzinga.com 26 Stocks Moving in Wednesday's Pre-Market Session Gainers Acasti Pharma Inc. (NASDAQ: ACST) rose 39% to $0.75 in pre-market trading after jumping 10% on Tuesday. The company reported a narrower FY21 loss.
businesswire.com Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq:GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular…
fool.com 3 Biotech Stocks With Big Catalysts in June Important events on the horizon could push these biotech stocks higher or press them further into the dirt.- benzinga.com 58 Biggest Movers From Yesterday Gainers Peabody Energy Corporation (NYSE: BTU) shares gained 32.3% to settle at $8.60 on Monday.
businesswire.com Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular…- benzinga.com 56 Biggest Movers From Yesterday Gainers Bridgford Foods Corporation (NASDAQ: BRID) shares surged 46.2% to close at $20.74 on Tuesday.
businesswire.com Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular…
businesswire.com Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021